drugset

drugset / Trial / NCT04688775

Eptinezumab in Participants With Episodic Cluster Headache

NCT04688775 ↗

Phase 3 Completed 231 enrolled H. Lundbeck A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)

Timeline

Start: 2020-12-23
Primary completion: 2023-06-14
Completion: 2023-10-05

Publications

Jensen RH, Tassorelli C, Tepper SJ, Charles A, Goadsby PJ, Snoer AH, Sperling B, Krog Josiassen M, Borgen Linander C, Ettrup A, Boneva N. Efficacy and Safety of Eptinezumab in Episodic Cluster Headache: A Randomized Clinical Trial. JAMA Neurol. 2025 Jul 1;82(7):706-714. doi: 10.1001/jamaneurol.2025.1317.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eptinezumab	Monoclonal antibody	400 mg	Intravenous

Indications